The company spent eight months attempting to sell off the Indian company it had acquired in 2013 for R745 million (about Rs 328 crore) in the hope of taking advantage of the growth in the medicines market in India.
But for the past two years, Adcock Ingram has notched up heavy losses of more than R50 million annually amid a struggle to make inroads in the highly competitive Indian market.
"The Indian pharmaceutical marketing and selling business does not meet the company's current investment criteria and as a result the company has decided to exit this business," Adcock Ingram said in a statement.
The disposal is subject to approval by the Foreign Investment Promotion Board in India and the separation of the regulatory services business from Adcock Healthcare, the statement added.
Also Read
The effective date of the disposal is expected to be end July 2016 unless the parties agree otherwise.
Analysts said the separation of the businesses was a strategic move which would allow Adcock Ingram to take advantage of cheaper manufacturing costs in India and market products in South Africa.
Adcock Ingram confirmed that due to the pressure on regulatory services in South Africa and a shortage of skills in this area, the Indian regulatory services business remained an important complement to its South African regulatory structure.